full comment requir non-u analyst conflict disclosur
pleas click link
fresh start opportun growth initi outperform
initi coverag outperform
enter datacent dragon
get cycl revisit valuat framework
take remain compel rraml continu matur
updat arrow data confirm enhanc kyproli profil
herceptin biosimilar abp get fda timelin unimpair
takeaway weekend dataset
thought new data point net posit
take orr data trial improv focu still commerci
take enfortumab polatuzumab continu look promis pivot trial
topacio ovarian updat larg increment focu remain tnbc
postcard boston solid fundament high investor interest
updat ep estim ccar
manag chang posit strength
fca equiti option potenti capit bad eps/growth
price prior day market close estimate unless otherwis note
question
expect
updat loan flat week
news nashvil
 of daili summari
continu growth sign
specialti pharma
focus week
week ahead analyst
power execut
look thing
week june
weekli perspect healthcar industri compani news valuat updat
continu digest learn last week
top investor question week payment processor servic
neulasta action date apss focu high teva confer prep
cover ccar bank expect total return increas
june new york citi
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
valu usd unless otherwis note
valu usd unless otherwis note
fresh start opportun growth initi outperform
axa equit matur well-establish retir product compani
lead market posit balanc sheet clean legaci concern
excess capit independ compani posit deliv earn
growth capit return drive rise roe initi outperform
price target
see axa equit rel straightforward stori establish
franchis opportun improv result growth capit
manag cost cut success compani doesnt need
transact higher interest rate run-off turnaround view
stori work well right even better action
well within manag control expect roe improv
next two year compani implement variou busi
three key lever earn growth compani target
annual earn growth see achiev
combin gener account reposit cost cut product
posit growth major segment compani flagship
individu retir unit expect growth achiev new
product expand distribut includ third-parti sale
capit return strong balanc sheet capit return like part
busi model right away plan dividend share repurchas
compani rel clean legaci book busi long-term
care exposur larg close block distract result compani
hedg risk manag program conserv posit
initi coverag outperform
ideal small cap cyclic growth fund manag look direct
exposur complet water solut busi tangenti exposur
frac wttr futur gener enabl opportunist
front lead edg new technolog dynam help
drive share gain maintain market-lead posit water solut
initi coverag outperform price target
price target base ebitda peer group
ev/ebitda rang target multipl reflect view
abl increas market share scale logist water monitor
enter datacent dragon
recent meet gd ceo cfo highlight compani strong sale
pipelin increas focu resourc procur grow develop
pipelin captur rise demand reiter outperform rate rais
pt
recent meet gd ceo cfo highlight compani strong
sale pipelin increas focu resourc procur grow
develop pipelin captur rise demand reiter outperform
rate rais pt
capit fund custom variou topic
reiter outperform rate rais pt
market data usd financi data cni dividend paid
valu cad unless otherwis note
morn oncolyt disclos price detail public offer
initi announc yesterday close view issuanc overli
surpris given recent clinic corpor develop compani
overal view onc remain unchang continu view favour
set-up
thought list overal view compani decis
re-list favour opinion manag continu
turnaround began year compani expand clinic
program gear ph reolysin program also believ time
re-list benefici addit believ investor interest
compani grow part driven broader interest oncolyt
issuanc price compani issu new share
current outstand offer price result
gross proce assum transact fee appli
usd/cad fx rate estim net proce follow
transact total share outstand would increas repres
dilut exist holder
step new offer provid addit financ
believ investor focu remain potenti anoth licens deal
addit look toward time initi ph reolysin
studi later year
model revis valuat updat chang outlook
compani follow recent corpor event said
adjust estim share consolid public offer
price target
get cycl revisit valuat framework
review valuat cyclic framework
valu usd unless otherwis note
valu usd unless otherwis note
need know continu think current nand cycl
downturn like milder investor expect acknowledg
cycl inextric tie valuat context review
valuat cyclic framework look multipl scenario nand declin
combin scenario potenti deterior hdd busi evalu
peak/trough scenario look like view like trough
scenario nand would impli asp declin bit grow
cost per bit declin scenario would yield nand gm
toward low end sandisk saw histor bar
trough case also expect hdd asp volum declin mid
singl digit cost declin low singl digit scenario see
gener trough ep impli normal ep
stock valuat histor multipl fundament current
stock price impli downsid ep narr unlik occur
bar materi econom shock net/net maintain op rate adjust
price target base normal ep
take remain compel rraml continu
weekend present updat data ivosidenib
inhibitor rraml inhibitor glioma
solid tumor ivosidenib saw larg increment updat os
slightli improv safeti remain larg line report
saw limit data initi dose escal trial sign
efficaci toler dose continu focu addit
present ivosidenib chemo combin idhmut aml
build limit data seen gain clariti additive/synergist
efficaci aml
see multipl posit readthrough aldr today
aimovig put strong rx number first week launch
chmp ok aimovig reaffirm regulatori comfort around
benefit cgrp class posit epti
valu usd unless otherwis note
updat arrow data confirm enhanc kyproli profil
show kyproli dose maintain advantag profil
current twice-weekli label r/r mm present updat data
arrow trial assess once-weekli kyproli
dexamethason kd vs twice-weekli dose dexamethason
patient r/r mm arrow includ patient receiv two
three prior line therapi top-lin data present in-lin
previous announc top-lin data octob showcas month
improv compar twice-weekli regimen addit
dose result significantli improv orr vs
improv cr rate vs safeti profil
two treatment arm similar new safeti risk emerg
valu usd unless otherwis note
herceptin biosimilar abp get fda timelin unimpair
tight-lip detail surround abp reject made
brief two-sent announc afternoon fda reject
bla abp biosimilar version herceptin roch pend updat
management expect delay major effect model
current forecast abp launch follow patent expir
herceptin june current model abp reach peak sale
valu usd unless otherwis note
interest highlight includ tout car-t cll reassur around
analys prospect potenti off-label use revlimid fl
valu usd unless otherwis note
new transcend result show competit profil dlbcl
hard know sure whether inde offer compar efficaci
yescarta much lower tox
caveat efficaci look competit
continu low rate
valu usd unless otherwis note
new ph ii myeloma data includ new follow-up previously-
report dose-escal pt earli respons data dose-expans pt
continu show promis overal profil
solid especi mrd neg pt though discuss durability/
advers event look quit accept along activ independ
valu usd unless otherwis note
takeaway weekend dataset
keytruda monotherapi data rcc could increas competit market
q-twist qualiti life analysi differenti ipinivo
io doublet combo continu show promis chemo-refractori muc
valu usd unless otherwis note
thought new data point net posit
thought point script inflect stave concern opdivo
yervoy market share eros rcc set caboatezo continu expand
protocol amend includ addit patient cohort
benefit appear wane time
valu usd unless otherwis note
valu usd unless otherwis note
take orr data trial improv focu still
kadcyla neratinib combo see improv efficaci tox limit dose
saturday updat data trial neratinib
kadcyla trastuzumab-emtansin patient tastat bc
present combo show orr respons efficaci
evalu patient cr pr remain patient evalu efficaci
stabl diseas progress diseas gi tox remain concern
trial dose neratinib vs approv dose move
forward combin stage trial
metastat bc patient present patient enrol
studi primari aim stage studi identifi safeti
toler neratinib identifi recommend dose
carri treatment stage studi includ dose
neratinib dose oral qd escal dose
mg patient includ studi previous treat
chemotherapi trastuzumab pertuzumab
valu usd unless otherwis note
valu usd unless otherwis note
take enfortumab polatuzumab continu look promis pivot
weekend present updat enfortumab vedotin
ev trial metastat urotheli carcinoma partner roch present
polatuzumab vedotin pola studi follicular lymphoma dlbcl data
last seen ev updat particularli treat prior checkpoint
inhibitor cpi remain compel deepen orr os compar
on-going potenti pivot studi popul pola data
dlbcl line report though exact addit benefit
though note pola meaning driver valuat potenti
upsid model given pola develop roch genentech
leverag platform receiv royalti
topacio ovarian updat larg increment focu remain tnbc
today tsro present increment updat topacio
studi assess zejula keytruda pembrolizumab pembro platinum-
resistant/refractori ovarian cancer proc similar data present sgo see
note orr data present rang across biomark
stratifi sub-typ popul evalu platinum-resistant/refractori
patient orr present line data
report previous sgo
postcard boston solid fundament high investor interest
investor meet outperform-r gate
leadership team boston june continu impress
healthi margin solid convers balanc price-cost tap
global manufactur capac new plant come on-line primari pushback
continu financi sponsor overhang net leverag
highlight boston investor meet host pack day
investor meet ceo ivo jurek cfo dave naemura vice-president ir
waelk june boston overarch take-away gate
invest thesi remain intact compani continu execut well
gate global leader highli engin industri belt hose
gener sale resilient/less cyclical/mor profit
aftermarket sale come busi gate hold
market share posit addit gate product use critic
applic high cost downtim oper lead
activ replac cycl gate product adjust ebitda gross
margin convers reflect solid profit
cash flow heard impress specif compani key growth initi
chain-to-belt convers extend fluid power product expand
emerg market expect lot question share
price under-perform sinc ipo two primari area pushback
continu financi sponsor overhang net leverag
capit alloc manag expect remain conserv de-lev
toward goal net leverag month today
outsid manag control expect blackston ratchet
ownership posit time shareholder-friendli way
updat ep estim ccar
adjust estim reflect estim total
billion capit return ccar cycl
adjust estim reflect estim total
billion capit return ccar cycl versu earlier estim
valu usd unless otherwis note
valu usd unless otherwis note
manag chang posit strength
palo alto name new chairman ceo releas strong third quarter bill
revenu product revenu friday manag transit
unexpect believ mr arora extrem strong hire compani
transit manag posit strength follow good result
maintain op pt
palo alto network name nikesh aurora new chairman ceo
current chairman ceo mark mclaughlin move vice chairman
releas bill revenu product revenu well guidanc
consensu move earn confer call et
chanc talk sever contact believ hire
extrem well receiv googl mr arora quickli move within inner
manag circl esteem went presid
softbank like choic sever high profil public privat unicorn
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
ceo posit believ mr arora bring strong go-to-market view
help palo alto scale next level growth also believ well
connect bring good understand importantli think
cloud background aid palo alto phase hybrid-cloud growth
also believ manag team around mr arora strong includ mark
presid rene bonvani klarich cpo nir zuk
fca equiti option potenti capit bad eps/growth
sc announc today talk fiat chrysler automobil fca exercis
equiti option acquir some/al chrysler capit busi limit
detail provid capit freed-up could sizabl concern
eps/growth could also meaning impair valuat ep
book excess risk vs return still less attract us
fca discuss chrysler capit sc announc today talk
fiat chrysler execut equiti option agreement eoa wherebi fca
would acquir equiti stake chrysler capit busi confirm media
report earlier week
could stay/go unclear forget leas book base
manag commentari exercis eoa could result rang
outcom transfer busi minority/port chrysler
capit loan/leas origin sizabl total
total loan chrysler along leas
portfolio leas portfolio pre-provis nii provis
sizabl may get overlook mani vs loan
news capit bad news eps/growth sc would recogn
moder gain fair valu transfer occur assum
chrysler loans/leas would part eoa new could
free meaning capit sc estim bad news unless sc
meaning ramp origin loan would declin earn could
meaning impair believ transfer loans/leas could even
result quarterli loss time
model volatil ex still high macroeconom trend
support delinqu worsen significantli though loss sever
rate volatil subprim mix would presum increas
transfer loans/leas
question med-tech manag
med-tech question pack includ question regard
coverag univers ask upcom confer provid question
follow compani elgx ew
ktwo
auto may better expect
may us light-vehicl came last year
rbce/bloomberg consensu may sale
unit y/i sda ford sale y/i sda
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
retail y/i fleet y/i recal gm stop report monthli
sale howev estim sale y/i sda vs
origin estim y/i sda bring ytd
summar notabl takeaway relev cover compani
celg
celg car-t product perform gener expect littl bake
celg share pipelin could see improv tone
around stock
analysi efficacy/safeti diseas burden seem make
doc confer comfort rel wors tox profil
may much due popul enrol
properti car-t construct
pt high ldh prev-treat
though discuss seal selinexor liposarcoma ph ii studi found
chang criteria signific differ
observ tumor assess key weak
studi nonetheless found median use recist sel
arm quit encourag promis believ drug activ
set
valuat tabl power price frac spread data rel price perform
ex-dividend date pleas see page detail valuat tabl
design highlight news supply/demand
develop global agricultural/equip market could impact
coverag among coverag oem deer greatest
exposur ag market weight north america
usda crop progress report show corn plant done wk end may
w/w vs prior yr average corn character
excel y/i average soybean plant
complet w/w y/i average mid-west expect
hot dri area favor elsewher heat subsid
valu usd unless otherwis note
valu usd unless otherwis note
rais quarterli dividend prior
mexico announc tariff sever us product incl pork leg appl grape
chees respons steel/aluminum action
look thing
quick take investor meet past week
investor interest of definit increas time mid-jun roll
around road front investor consecut
week stark contrast three separ market
trip three differ region cancel due insuffici demand
primari topic interest includ
frac servic permian take-away risk factor
off-shore drill becom part mainstream discuss
continu push us land drill
global energi power confer june
perfect time get read earli take well
permian take-away capac upcom opec meet imo
interest strong investor regist attend effect flat
aggreg energi compani across globe includ
major oil util of compani cover entir food chain
june edit global energi best idea list hit press
may global energi best idea list vs global energi
sinc incept februari global energi best idea list
outperform ixc vs ixc
updat loan flat week
weekli industri loan flat non-season adjust loan flat week-
over-week w/w basi end may year-over-year
y/i basi follow trend
commerci industri w/w y/i
consum w/w y/i
commerci estat w/w y/i
residenti estat w/w y/i
equiti w/w y/i
w/w y/i
week june
what wrong life insur much there question life insur
share under-perform far year look commonli cite reason
includ interest rate concern re-emerg volatil black-box account
blow-up long-term care strong fundament address
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
see pro con argument bottom line
under-own sector inexpens valuat think merit fresh look
investor particularli view interest rate econom tailwind
recommend prudenti favorit idea along lincoln princip
record year worker compens take look worker
compens data ncci provid thought
 industri largest commerci line industri data show privat market
worker comp carrier gener impress combin ratio last year
better overal industri vs wc last year
third consecut year wc report underwrit profit line
histor hasnt profit
reput insur last week learn misbehav
on-line costli least two exampl make nation news roseann
barr bryan colangelo loss could protect form
insur known reput risk insur comment recent
milliman articl overview reput insur chang risk
analyz perform thru first five month week take look
midstream name across coverag univers perform ytd
rest energi space perform well ahead due
favor commod price backdrop increas produc activ midstream
energi compani under-perform primarili due increas volatil
driven chang regul ferc uncertainti around consolid
howev note midstream energi perform bad seem
instanc exclud midstream name impact ferc polici
statement eep sep tcp dm bwp ytd price return total return
coverag univers weighted-averag basi outperform
respect particularli diversifi ps
outperform investor focu large-cap name
name expos commod price addit note mlp
across coverag univers outperform c-corp ytd mlp
vs c-corp weighted-averag price return basi look ahead
think key volatil stabil fund start flow back
space remaind
met coal price jump follow cp strike fell agreement reach
avanco suspend mine activ anta fmg approv develop
eliwana iron ore project india take step perman shut vedanta
copper smelter miner threaten legal action drc concern
mine code address acquir stake eagl down coal
project labrador iron ore reach labor agreement ioc copper began
wage talk peru coal india increas allot power plant
xcmg provid motor grader bhp iron ore project pilbara bhp billiton
mitsubishi allianc sell gregori crinum coke coal mine global steel prod
y/i zimbabw top miner produc coal expect
next two year au march qtr gold prod y/i eldorado gold got final
approv build tocantinzinho mine
maintain sector perform rate
news nashvil
weekli perspect healthcar industri compani news valuat
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
sector price perform week end june healthcar servic stock
under-perform broader market health servic select
spsihp declin versu gain
skill nurs strongest perform sub-sector last
week acut hospit downtick vs declin
prior week manag declin vs uptick prior week
specialti weakest perform sub-sector last week
hpc costco report may quarter comp sale without ga
inflat fx us canada intern
grew report april quarter compstore due increas
averag transact amount partial off-set declin custom traffic
report april quarter compstore miss headlin bottom
beverag launch first ever alcohol drink japan coca-
cola invest us billion argentina upgrad
exist facil construct new product line beverag africa
said would invest kenya next five year improv
infrastructur launch new product announc buy bare
food co maker fruit veget snack monster beverag board
tobacco philip morri sa urg south african govern creat
exempt new tobacco bill would enabl provid consum
inform heat tobacco product iqo japan tobacco inc set
slash price heat tobacco product earli june similar move
 reynold tobacco co contribut nearli
million proposit campaign urg voter reject ban
sell flavor tobacco product san francisco
continu digest learn last week
long salli cfo salli bailey retir juli announc
salli bailey cfo sinc join lp decemb elect retir
lumber price continu post increment gain amidst slower trade
holiday weekend spf inch syp price
osb price across region despit continu quiet trade
benchmark north central move
brazil trucker strike latest suppli shock pulp market could
much wors strike eas latest string
key suppli disrupt kept global market pulp industri tighter
anticip sinc overal brazil account global hardwood
kraft market pulp capac prolong impedi brazilian product
would signific issu tissu produc around world
pulp accord risi final may nbsk effect list price close
tonn sbsk announc may
price produc june price could rise still without fresh round
announc hike produc would move solidifi list level
unexpectedli strong us nbsk spot price may break resist among
buyer howev domest nbsk net price appar stall
china price market particip watch chines pulp price close
top investor question week payment processor servic
valu usd unless otherwis note
valu gbp unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
quick summari question topic includ ii season continu still need
vote might miss sq potenti mobil
payment usag prioriti fraud emv adopt best worst
perform stock week respect thursday close
thursday close
engi exclus talk petroba brazilian ga pipelin network
swansea bay tidal lagoon reject week
intern of daili
capit market global energi power execut confer
semiconductor may pmi indic continu growth sign
deceler
continu growth almost major geographi unit state pmi
decreas driven strong expans
output new order japan pmi decreas
signal softer growth momentum japanes manufactur
sector eurozon pmi decreas rate expans
output new order slow china pmi remain flat
signal margin improv manufactur sector
south korean pmi increas vs taiwan pmi
decreas product growth
slow aggreg think pmi data point continu improv
manufactur activ key geographi track albeit experienc slower
rate growth bode posit industrial-focus compani
 focu within coverag area remain name
host self-help lever dispos drive ep growth even
revenu growth remain mute recommend large-cap
mid-cap
specialti pharma focus week
neulasta action date apss focu high teva confer prep
focu past week sector squar like
continu week compani provid result await
strateg review link stock reaction mute heard signific
push-back recur question base incom call whether
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
sharehold push chang becom formal/voc like
remain focu week see primer/strateg report background link
host dinner thur chairman/ceo bruce cozadd link
come ahead webcast apss tue et final debat
high around whether partner biocon get approv neulasta
biosimilar expect color mon
host kol clinician/research major academ center special
cellular therapi dinner kol
somewhat posit celg/blu data
believ vs efficaci safeti differ like real
predilect yescarta dlbcl despit increas toxic given
manag neurotox experi
see clear path toward car-t move earlier line dlbcl
week ahead pre-announc friday
report result host meet manag attend
sap sapphir also visit client europ
lot good takeaway mari meeker internet trend highlight
extrem growth network order last year
connect signific enabl mobil cloud applic adopt
recap manag chang elli also recap earn
cover ccar bank expect total return increas
aggreg nomin amount capit return expect increas
billion billion averag pay-out group
declin slightli earn capit market bank expect
hit hardest year scenario believ gs ms
could lower amount capit return versu ccar
last year first year sinc ccar implement bank pass
ccar stress test expect bank pass year believ
howev risk qualit failur elev compani
due extran issu
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
watt mind
past week spent time valu investor would expect
name discuss fallen angel fe lesser extent
lower price-to-earnings name progress made
address california wildfir gener view long invers
condemn appli util remain featur california law
littl appetit investor view current legisl effort
open regulatori interpret work well
compani far investor optimist point role
util need play california de-carbon goal
get question part stock
perform well year-to-d relat util vs uti
recent weaker quarter-to-
date vs uti argu mani key
catalyst done zec pjm capac auction lead period reduc
investor interest continu believ discount unwarr
re-rat manag execut
week ahead analyst event sector thought
week med-tech host analyst event digest diseas
week washington dc member endoscopi leadership team
present one-hour event besid endoscopi oper perform
manag present session like cover new product
expect launch next year also biennial investor day
held june nyc event focu forecast
capit market global energi power execut
june new york citi
capit market global energi power execut confer
held june new york approxim compani close
institut investor attend report capit market
global energi research identifi key invest theme
question present compani brief outlin view oil ga
commod price also includ chief us equiti strategist lori calvasina
contribut macro perspect space conveni
also includ full two-day agenda hope find report
help alway encourag reach global energi
discuss regard invest idea
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict
capit market may restrict publish research report time time due regulatori restrict and/ intern complianc polici
case latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject
compani capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri
busi secur broker dealer jurisdict full extent permit law neither capit market affili
person accept liabil whatsoev direct consequenti loss aris use report inform contain herein matter
contain document may reproduc copi mean without prior consent capit market
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
